SCHEMBL17239377

SCHEMBL17239377

C=CC(C)(O)CCC[C@H](C)CCC[C@H](C)CCCC(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 3/20 1.00
MEN1 O00255 1/20 1.00
CYP3A4 P08684 1/20 1.00
KMT2A Q03164 1/20 1.00
LMNA P02545 1/20 0.48
PTPN1 P18031 3/20 0.44
PTPN2 P17706 1/20 0.44
CDC25B P30305 1/20 0.44
BLM P54132 1/20 0.41
PTGS1 P23219 1/20 0.31
PDE4A P27815 1/20 0.31
SNCA P37840 1/20 0.31
PDE3A Q14432 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8082488 1.00 ALOX15 (1.00) ALOX15MEN1CYP3A4KMT2ALMNA
SCHEMBL21429 1.00 ALOX15 (1.00) ALOX15MEN1CYP3A4KMT2ALMNA
SCHEMBL29659795 1.00 ALOX15 (1.00) ALOX15MEN1CYP3A4KMT2ALMNA
SCHEMBL4437129 1.00 ALOX15 (1.00) ALOX15MEN1CYP3A4KMT2ALMNA
SCHEMBL8079400 1.00 ALOX15 (1.00) ALOX15MEN1CYP3A4KMT2ALMNA
SCHEMBL15824175 1.00 ALOX15 (1.00) ALOX15MEN1CYP3A4KMT2ALMNA
Alcohol SCHEMBL11523426 0.95 ALOX15 (0.90) ALOX15MEN1CYP3A4KMT2ALMNA
SCHEMBL722489 0.92 ALOX15 (0.85) ALOX15MEN1CYP3A4KMT2ALMNA
SCHEMBL30492702 0.92 ALOX15 (0.85) ALOX15MEN1CYP3A4KMT2ALMNA
SCHEMBL28826305 0.90 ALOX15 (0.81) ALOX15MEN1CYP3A4KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109970533-B (6R,10R) -6,10, 14-trimethylpentadecan-2-one prepared from (R) -6,10, 14-trimethylpentadeca-5-en-2-one 帝斯曼知识产权资产管理有限公司 2022-06-14 CN claimed
EP-2935177-B1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE DSM IP ASSETS BV (NL) 2019-07-24 EP claimed
EP-2935185-B1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10,14-TRIMETYLPENTADECA-5,9,13-TRIEN-2-ONE OR 6,10,14-TRIMETYLPENTADECA-5,9-DIEN-2-ONE DSM IP ASSETS BV (NL) 2019-02-20 EP claimed
EP-2935181-B1 EFFICIENT PROCESS OF ASYMMETRIC HYDROGENATION OF UNSATURATED KETONES USING ADDITIVES DSM IP ASSETS BV (NL) 2019-01-30 EP claimed
EP-2935233-B1 PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS DSM IP ASSETS BV (NL) 2019-01-30 EP claimed
EP-2935175-B1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM (R)-6,10,14-TRIMETYLPENTADEC-5-EN-2-ONE DSM IP ASSETS BV (NL) 2018-09-19 EP claimed
EP-2935190-B1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDECA-3,5,9-TRIEN-2-ONE DSM IP ASSETS BV (NL) 2018-09-19 EP claimed
EP-2935176-B1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM (R)-3,7-DIMETYLOCT-6-ENAL DSM IP ASSETS BV (NL) 2018-08-01 EP claimed
EP-2935191-B1 PREPARATION OF (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE FROM 3,7-DIMETYLOCT-2-ENAL OR 3,7-DIMETYLOCTA-2,6-DIENAL DSM IP ASSETS BV (NL) 2018-08-01 EP claimed
US-9611200-B2 (6R,10R)-6,10,14-trimetylpentadecan-2-one prepared from 6,10,14 trimetylpentadeca-5,9,13-trien-2-one or 6,10,14-trimetylpentadeca-5,9-dien-2-one DSM IP ASSETS B.V. (NL) 2017-04-04 US claimed
US-9452961-B2 (6R,10R)-6,10,14-trimetylpentadecan-2-one prepared from 6,10-dimetylundec-5-en-2-one or 6,10-dimetylundeca-5,9-dien-2-one DSM IP ASSETS B.V. (NL) 2016-09-27 US claimed
US-20160185683-A1 PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS DSM IP ASSETS B.V. (NL) 2016-06-30 US claimed
US-20150329457-A1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE DSM IP ASSETS B.V. (NL) 2015-11-19 US claimed
US-20150329456-A1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10,14 TRIMETYLPENTADECA-5,9,13-TRIEN-2-ONE OR 6,10,14-TRIMETYLPENTADECA-5,9-DIEN-2-ONE DSM IP ASSETS B.V. (NL) 2015-11-19 US claimed
US-20150321971-A1 EFFICIENT PROCESS OF ASYMMETRIC HYDROGENATION OF UNSATURATED KETONES USING ADDITIVES DSM IP ASSETS B.V. (NL) 2015-11-12 US claimed
CN-109970533-B (6R,10R) -6,10, 14-trimethylpentadecan-2-one prepared from (R) -6,10, 14-trimethylpentadeca-5-en-2-one 帝斯曼知识产权资产管理有限公司 2022-06-14 CN disclosed
EP-2935177-B1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE DSM IP ASSETS BV (NL) 2019-07-24 EP disclosed
US-20150329457-A1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE DSM IP ASSETS B.V. (NL) 2015-11-19 US disclosed
US-20150321971-A1 EFFICIENT PROCESS OF ASYMMETRIC HYDROGENATION OF UNSATURATED KETONES USING ADDITIVES DSM IP ASSETS B.V. (NL) 2015-11-12 US disclosed
US-20150321986-A1 USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINED ASYMMETRIC HYDROGENATIONS DSM IP ASSETS B.V. (NL) 2015-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329456-A1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10,14 TRIMETYLPENTADECA-5,9,13-TRIEN-2-ONE OR 6,10,14-TRIMETYLPENTADECA-5,9-DIEN-2-ONE CYP3A5, ADRA1D, HTR5A ALOX15 756/4885MEN1 3261/4885CYP3A4 81/4885
US-20150321971-A1 EFFICIENT PROCESS OF ASYMMETRIC HYDROGENATION OF UNSATURATED KETONES USING ADDITIVES ADH5, ADH1A, ADH1C ALOX15 171/4885MEN1 4403/4885CYP3A4 386/4885
US-20150321986-A1 USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINED ASYMMETRIC HYDROGENATIONS EPHX2, HBZ, ELOVL5 ALOX15 104/4885MEN1 1465/4885CYP3A4 247/4885
US-20160185683-A1 PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS KAT5, AKR1D1, AKR1C2 ALOX15 177/4885MEN1 3222/4885CYP3A4 1268/4885
US-20150329457-A1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE PDE12, CYP2D6, PDE9A ALOX15 731/4885MEN1 1634/4885CYP3A4 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.